Loading
A phase 1/2 trial of Enzalutamide in diffuse large b-cell lymphoma and mesothelioma, run by Novartis Pharmaceuticals, now recruiting.
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas is a phase 1/2 interventional study registered as NCT04104776 by Novartis Pharmaceuticals, with 300 participants planned, started 2019-09-18 and due to reach its primary completion in 2030-02-27. Interventions recorded: Tulmimetostat, Enzalutamide. Conditions listed: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Novartis, Prostate cancer.
Shares Androgen deprivation & AR pathway inhibitors, Novartis, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/